Hyperprolactinemia (Drug-Induced, Physiologic, and Pathologic)

Risk factors

• Antipsychotic use, particularly risperidone, paliperidone, haloperidol, and other first-generation agents; less so olanzapine and quetiapine; aripiprazole is partial dopamine agonist and usually does not elevate prolactin
• Antiemetics — metoclopramide, prochlorperazine, promethazine, domperidone
• Antidepressants — selective serotonin reuptake inhibitors, tricyclics, monoamine oxidase inhibitors (modest elevations)
• Opioids — methadone, morphine, oxycodone
• Estrogens, including combined oral contraceptives (mild elevation)
• Verapamil, methyldopa, reserpine, H2 blockers (cimetidine)
• Pregnancy and lactation
• Pituitary mass causing stalk compression (any sellar lesion)
• Primary hypothyroidism (TRH stimulates prolactin)
• Chronic kidney disease, cirrhosis (decreased clearance)
• Chest wall trauma or surgery, nipple stimulation (reflex)

Pathophysiology

Prolactin secretion by anterior pituitary lactotrophs is under tonic inhibition by hypothalamic dopamine acting on D2 receptors. Any process that reduces dopaminergic tone — dopamine receptor antagonists, dopamine depleting drugs, opioid suppression of dopamine release, or interruption of the pituitary stalk (stalk effect from any sellar mass) — increases prolactin. In primary hypothyroidism, elevated thyrotropin-releasing hormone (TRH) stimulates both TSH and prolactin secretion. In chronic kidney disease and cirrhosis, decreased clearance contributes. Prolactin elevation suppresses GnRH pulsatility, producing hypogonadotropic hypogonadism (amenorrhea, infertility, low libido, erectile dysfunction).

Clinical presentation

Differential diagnosis

• Prolactinoma (microadenoma <10 mm, macroadenoma ≥10 mm) — Persistent prolactin elevation correlating with tumor size; prolactin >250 ng/mL strongly suggests prolactinoma; MRI sella
• Drug-induced hyperprolactinemia — Temporally related to medication; typically 25-100 ng/mL, rarely >200; resolves within weeks of discontinuation; no MRI lesion
• Stalk effect from non-prolactin-secreting sellar mass — Modest elevation (typically 25-150 ng/mL, rarely >200); MRI shows non-prolactinoma sellar/parasellar mass
• Primary hypothyroidism — Elevated TSH; prolactin normalizes with thyroid hormone replacement
• Pregnancy — Beta-hCG positive; prolactin physiologically rises through pregnancy
• Macroprolactin (laboratory artifact) — High molecular weight prolactin-IgG complex; biologically inactive; suspect when prolactin is elevated but patient is asymptomatic; polyethylene glycol (PEG) precipitation test
• Chronic kidney disease, cirrhosis — Decreased clearance; modest elevations
• Idiopathic hyperprolactinemia — Diagnosis of exclusion after MRI and all other causes ruled out

Diagnostic workup

Diagnostic algorithm

flowchart TD
  A[Elevated prolactin] --> B[Confirm + repeat<br/>quiet venipuncture]
  B --> C[Pregnancy test<br/>TSH, creatinine, LFTs<br/>Medication review]
  C --> D{Cause identified?}
  D -->|Pregnancy / lactation| E[Physiologic — no workup]
  D -->|Primary hypothyroidism| F[Treat with levothyroxine<br/>recheck prolactin]
  D -->|Drug-induced<br/>25-200 ng/mL| G[Stop or switch drug if feasible<br/>or use aripiprazole adjunct]
  D -->|Asymptomatic, modest elevation| H[Check macroprolactin<br/>PEG precipitation]
  D -->|No cause identified or<br/>prolactin >100 ng/mL or<br/>symptoms| I[MRI sella<br/>with gadolinium]
  I --> J{Imaging finding?}
  J -->|Microadenoma <10 mm| K[Dopamine agonist<br/>cabergoline or bromocriptine<br/>if symptomatic]
  J -->|Macroadenoma ≥10 mm| L[Full pituitary panel<br/>+ visual fields<br/>+ dopamine agonist]
  J -->|No tumor| M[Idiopathic<br/>treat if symptomatic]
  L --> N{Hook effect suspected?<br/>large tumor, modest prolactin}
  N -->|Yes| O[Repeat prolactin<br/>at 1:100 dilution]

Treatment

Complications

• Hypogonadotropic hypogonadism — amenorrhea, infertility, low libido, erectile dysfunction
• Osteoporosis and fragility fractures from chronic hypogonadism
• Visual field loss, cranial nerve palsies, and hypopituitarism from macroadenoma compression
• Pituitary apoplexy — sudden hemorrhage or infarction of the adenoma with severe headache, ophthalmoplegia, and adrenal crisis
• Dopamine agonist side effects: nausea (start at bedtime with food), orthostatic hypotension, nasal congestion, impulse control disorders (pathologic gambling, hypersexuality, binge eating); rare valvular fibrosis at high cumulative doses
• Pregnancy considerations — bromocriptine has longer safety data; many discontinue dopamine agonist after pregnancy confirmed if microadenoma; macroadenomas warrant continued therapy and close visual field surveillance

PANCE pearls

• The most common cause of hyperprolactinemia in clinical practice is medication — review every drug list carefully (antipsychotics, antiemetics, antidepressants, opioids, methyldopa, verapamil) before ordering MRI.
• Prolactin >250 ng/mL is highly suggestive of a prolactinoma; values 25-100 ng/mL are more typical of drug effect, stalk effect, primary hypothyroidism, or renal/hepatic disease.
• Beware the HOOK EFFECT — very large prolactinomas can produce so much prolactin that the immunoassay paradoxically reports a low value; if a large pituitary mass is found but prolactin is unexpectedly modest, request a 1:100 dilution to rule out hook artifact.
• Macroprolactin is a biologically inactive prolactin-IgG complex that elevates the lab value without causing symptoms — suspect when an asymptomatic patient has high prolactin and confirm with polyethylene glycol (PEG) precipitation.
• Always check TSH and beta-hCG before chasing a prolactin elevation with MRI — both are easy to miss and cheap to exclude.
• Cabergoline at standard prolactinoma doses has a very favorable safety profile, but counsel every patient about impulse control disorders (gambling, hypersexuality) — these are reversible on dose reduction but easy to overlook.

References

• Endocrine Society 2011 — Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline (Melmed et al., J Clin Endocrinol Metab 2011)
• AACE/ACE 2011 — American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Pituitary Incidentalomas (Cook et al., Endocr Pract 2011)
• Pituitary Society 2006 — Guidelines of the Pituitary Society for the Diagnosis and Management of Prolactinomas (Casanueva et al., Clin Endocrinol 2006)
• Endocrine Society 2016 — Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (Fleseriu et al., J Clin Endocrinol Metab 2016)